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ium-1,2-diolate), two structurally similar diazeniumdiolate deriva-
tives, were designed as liver-selective prodrugs that are metabolized
by cytochrome P450 isoenzymes, with subsequent release of nitric
oxide (NO). Yet, their efficacy in the treatment of nonalcoholic fatty
liver disease (NAFLD) and their comparative pharmacokinetic and
metabolic profiles have not been characterized. The aim of the
present work was to compare the effects of V-PYRRO/NO and
V-PROLI/NO on liver steatosis, glucose tolerance, and liver fatty acid
composition in C57BL/6J mice fed a high-fat diet, as well as to
comprehensively characterize the ADME (absorption, distribution,
metabolism and excretion) profiles of both NO donors. Despite their
similar structure, V-PYRRO/NO and V-PROLI/NO showed differences
in pharmacological efficacy in themurinemodel of NAFLD. V-PYRRO/NO,
but not V-PROLI/NO, attenuated liver steatosis, improved glucose
tolerance, and favorably modified fatty acid composition in the liver.
Both compounds were characterized by rapid absorption following
i.p. administration, rapid elimination from the body, and incomplete
bioavailability. However, V-PYRRO/NO was eliminated mainly by the
liver, whereas V-PROLI/NO was excreted mostly in unchanged form
by the kidney. V-PYRRO/NO was metabolized by CYP2E1, CYP2C9,
CYP1A2, and CYP3A4, whereas V-PROLI/NO was metabolized mainly
by CYP1A2. Importantly, V-PYRRO/NO was a better NO releaser in
vivo and in the isolated, perfused liver than V-PROLI/NO, an effect
compatible with the superior antisteatotic activity of V-PYRRO/NO.
In conclusion, V-PYRRO/NO displayed a pronounced antisteatotic
effect associated with liver-targeted NO release, whereas V-PROLI/NO
showed low effectiveness, was not taken up by the liver, and was
eliminated mostly in unchanged form by the kidney.
Introduction
Many commonly used drugs do not possess biologic activity per se,
but are metabolized into active metabolites that exert a therapeutic effect.
Increasing bioavailability, reducing toxicity, and achieving organ-selective
delivery represent the major aims of prodrug development (Han and
Amidon, 2000; Huttunen et al., 2008; Testa, 2009). One of the strategies
for achieving hepatoselectivity in drugs is to develop prodrugs that are
metabolized by specific enzymes in the liver (Han and Amidon, 2000;
Erion et al., 2005; Zawilska et al., 2013). Since cytochrome P450–
dependent enzymes represent a large family of enzymes responsible for
metabolizing a vast number of xenobiotics, and are located mainly in the
liver, they constitute an excellent target for liver-specific prodrugs
(Huttunen et al., 2008; Ortiz de Montellano, 2013).
V-PYRRO/NO [O(2)-vinyl-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-
diolate] and V-PROLI/NO (O2-vinyl-[2-(carboxylato)pyrrolidin-1-
yl]diazen-1-ium-1,2-diolate) (Fig. 1) are both diazeniumdiolates that
were designed to deliver nitric oxide (NO) directly to the liver via cytochrome
P450–dependent metabolism. The structure of these prodrugs was designed
to avoid spontaneous decomposition under physiological conditions and to
facilitate cytochrome P450–related biotransformation into their respective
epoxides. These unstable intermediates are formed in hepatocytes and
hydrolyze, either spontaneously or via enzymatic reaction by hepatic epoxide
hydrolase, to generate diazeniumdiolate ions, which spontaneously release
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NO (Saavedra et al., 1997). It has been demonstrated that V-PYRRO/NO
metabolizes into biologically active NO in isolated hepatocytes but not
in liver sinusoidal endothelial cells, Kupffer cells, arterial vascular
smooth muscle cells, systemic endothelial cells, or murine macrophages,
underscoring the hepatocyte selectivity of NO delivery by V-PYRRO/
NO (Saavedra et al., 1997).
In turn, V-PROLI/NO is a novel proline-based analog of V-PYRRO/
NO with additional carboxylic acid moiety attached to the molecule to
improve the water solubility. Furthermore, the additional functionality
makes naturally occurring metabolite N-nitrosoproline the major product of
decomposition of V-PROLI/NO, resulting in a favorable toxicological
profile (Chakrapani et al., 2007; Hong et al., 2010). V-PYRRO/NO, on the
other hand, is metabolized to N-nitrosopyrrolidine, which is burned with
toxicity. To our knowledge, up to now, only one report has demonstrated
that V-PROLI/NO is metabolized to NO in human hepatocytes, and in that
report, immortalized human HepG2 cells were used (Qu et al., 2009).
In turn, in numerous reports, V-PYRRO/NO has been shown to
possess hepatoprotective effects, e.g., in tumor necrosis factor-a –induced
hepatitis (Saavedra et al., 1997) or acetaminophen-induced toxicity (Liu
et al., 2003), as well as in other in vitro and in vivo models of hepatocyte
injury (Kim et al., 2000b; Ricciardi et al., 2001; Liu et al., 2002, 2004,
2005; DeLeve et al., 2003; Li et al., 2003; Gong et al., 2004; Liu and
Waalkes, 2005; Qu et al., 2005, 2007; Edwards et al., 2008; Holownia
et al., 2009; González et al., 2011; Hu et al., 2013). Moreover,
V-PYRRO/NO–derived NO release in the liver was shown to be followed
by the elevation of liver cGMP with minimal systemic hypotensive
effects (Saavedra et al., 1997). In contrast, hepatoprotective activity by
V-PROLI/NO has only been reported in one study, which used the model
of arsenic-induced toxicity in human HepG2 cells (Qu et al., 2009).
The evidence shows that NO regulates lipogenesis/lipolysis and
controls gluconeogenesis/glycolysis pathways (Duplain et al., 2001;
Ijaz et al., 2005; Jobgen et al., 2006). Overexpression of endothelial
nitric oxide synthase has consistently been demonstrated to protect
against obesity, hyperinsulinemia, adipocyte hypertrophy, decreased
plasma triglycerides, and free fatty acid plasma concentration (Sansbury
et al., 2012). On the other hand, impaired NO bioavailability has been
shown to result in the development of hypertension, insulin resistance,
and obesity—being at least in part a consequence of impaired fatty acid
oxidation (Duplain et al., 2001; Cook et al., 2003; Le Gouill et al., 2007).
Accordingly, liver-selective release of NO could represent an effective
novel strategy for preventing nonalcoholic fatty liver disease (NAFLD).
The aim of the present study was to compare the therapeutic effects of
V-PYRRO/NO and V-PROLI/NO against high-fat diet (HFD)–induced
liver steatosis and insulin resistance, as well as to comprehensively




Chemicals such as high-performance liquid chromatography–grade acetonitrile,
formic acid, and methanol were purchased from Merck (Darmstadt, Germany).
Ketamine, heparin, and isoflurane were bought from PGF Cefarm (Kraków,
Poland). Xylazine, sodium chloride, calcium chloride, magnesium sulfate, sodium
bicarbonate, potassium dihydrogen phosphate, glucose, pyruvic acid, EDTA, Tris
base, potassium chloride, sucrose, sodium phosphate dibasic, acetone, magnesium
chloride, NADPH, Folin & Ciocalteu’s phenol reagent, potassium-sodium
tartaretetrahydrate, copper sulfate, sodium hydroxide, phenacetin, acetaminophen,
tolbutamide, 4-hydroxytolbutamide, bufuralol, 1-hydroxybufuralol, chlorzoxazone,
6-hydroxychlorzoxazone, midazolam, 1-hydroxymidazolam, 4-hydroxymidazolam,
dextrorphan, furafylline, sulfaphenazole, (+)-N-3-benzylnirvanol, quinidine, disulfiram,
and ketoconazole were purchased from Sigma-Aldrich (St. Louis, MO). Water
used in the study was prepared using a Milli-Q system (Millipore, Billerica, MA).
V-PYRRO/NO and V-PROLI/NO (.99% pure) were synthetized at the Center
for Cancer Research at the National Cancer Institute in Frederick, MD, as
described previously (Saavedra et al., 1997; Chakrapani et al., 2007).
Animals
Male C57BL/6J mice (16–25 g) and Wistar rats (180–220 g) were purchased
from Charles River Laboratories (Raleigh, Germany). Animals were housed
in colony cages in a room with constant temperature (21–25C), a relative
humidity of 40–65%, a standard light/dark cycle, and access to food and water
ad libitum. Prior to experiments, the animals were fasted overnight with free
access to water. All procedures involving animals were conducted according to
the Guidelines for Animal Care and Treatment of the European Union and were
approved by the Local Ethical Committee for Experiments on Animals at the
Jagiellonian University (Krakow, Poland).
Pharmacological Study
Six-week-old, male, C57BL/6J mice were fed a HFD (60 kcal% of fat;
(Research Diets, New Brunswick, NJ) for 15 weeks. After 10 weeks of HFD
feeding, treatment with V-PYRRO/NO at 5 mg/kg (32 mmol/kg i.p. bolus two
times per day) or V-PROLI/NO at 6 mg/kg (29 mmol/kg i.p. bolus two times
per day) was carried out for an additional 5 weeks. At the end of the ex-
periment, the animals were anesthetized with ketamine (100 mg/kg, i.p.) and
xylazine (10 mg/kg, i.p.).
Glucose Tolerance Test. For the glucose tolerance test, the mice were fasted
for 4 hours and then injected intraperitoneally with saturated glucose solution (at
2 g/kg of body weight). Blood was collected from the tail veins prior to glucose
administration (0 minute) and at 15, 30, 45, 60, and 120 minutes following
administration. Plasma glucose concentrations were measured by the enzymatic
photometric method using an automatic biochemical analyzer Pentra 400 (Horiba,
Kyoto, Japan) according to the manufacturer’s instructions. Area under the curve
(AUC) of blood glucose concentration versus time was calculated using the
trapezoidal method.
Histologic Evaluation. Liver samples were fixed in 4% buffered formalin.
Samples were embedded in OCT (optimal cutting temperature) medium and frozen
at 280C, or prepared according to the standard paraffin method. OCT-embedded
7-mm sections were stained with Oil Red O for fat content examination. Paraffin-
embedded 5-mm sections were stained with hematoxylin and eosin for general
histology and one-step Gomori’s trichrome for fibrosis visualization. Sections were
photographed at 100 (Oil Red O) and 200 (H&E, one-step Gomori’s trichrome)
magnification with an Olympus BX51 light microscope (Olympus Corporation,
Tokyo, Japan). Four images of each Oil Red O–stained section (n = 6/group) were
analyzed for lipid content using the ImageJ software macro adapted for Oil Red O
staining (National Institutes of Health, Bethesda, MD).
Lipid Analysis. Liver samples (ca. 100 mg) were powdered in a mortar
precooled with liquid nitrogen followed by extraction of lipids in a chloroform-
methanol solution. The fractions of triacylglycerols (TAGs) were separated
using thin-layer chromatography, according to the methodology of Baranowski
et al. (2013) and Zabielski et al. (2010). Individual fatty acid methyl esters were
liberated by acid methanolysis using BF3MeOH, and were identified and quantified
according to the retention times of standards by gas-liquid chromatography (Agilent
5890 Series II gas chromatograph with flame ionization detector, Agilent CP-Sil88
capillary column, 50 m, 0.25-mm i.d., 0.2-mm film; Agilent Technologies, Santa
Clara, CA). Total TAG content was estimated as the sum of the particular fatty acid
species of the assessed fraction and expressed in nanomoles per gram of tissue. The
content of saturated fatty acids (SFA, C14:0, C16:0, C18:0, C20:0, C22:0, C24:0),
monounsaturated fatty acids (C16:1, C18:1, C24:1), and polyunsaturated fatty acids
Fig. 1. Structures of V-PYRRO/NO and V-PROLI/NO.
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(PUFA, 18:2 n-6, 18:3 n-3, 20:4 n-6, 22:6 n-3) in the TAG fractions was analyzed,
along with the PUFA/SFA ratio (Wierzbicki et al., 2009).
In Vivo Pharmacokinetics
The 6-week-old male C57BL/6J mice were injected with V-PYRRO/NO
or V-PROLI/NO as a single i.v. and i.p. administration at a dose of 5 mg/kg
(32 mmol/kg) or 6 mg/kg (29 mmol/kg) for V-PYRRO/NO and V-PROLI/NO,
respectively. Animals were anesthetized with isoflurane at a concentration of
3–4% in 100% oxygen and sacrificed at the following time intervals: 0 (before
dosing) and 2, 5, 7, 10, 15, 20, 25, 30, 45, 60, 90, 120, and 240 minutes after
compound administration. Blood samples were collected into heparinized
microfuge tubes and centrifuged at 1000 rpm for 15 minutes. The plasma was
separated into clean tubes and frozen at 220C prior to analysis. The liver
tissues were collected and rinsed with phosphate-buffered saline (pH 7.4) and
stored at 280C until analysis.
All data in the pharmacokinetic experiments were processed using Phoenix
WinNonlin 6.3 software (Certara, St. Louis, MO). The noncompartmental approach
was applied to calculate the basic pharmacokinetic parameters such as mean
residence time, AUC, systemic clearance (ClT), and volume of distribution at
steady state.
Renal Clearance
After a single i.v. injection of V-PYRRO/NO (5 mg/kg) or V-PROLI/NO
(6 mg/kg), the 6-week-old mice (n = 7) were individually placed in stainless
steel metabolic cages for collection of urine. The urine samples were collected
at 0–6, 6–12, and 12–24 hours post dosing. The volumes of the urine samples
were recorded, and samples were stored at 220C until analysis.
Renal elimination was assessed based on the fraction of administered dose





where fR is the fraction of dose excreted by the kidney, Ae
‘ is the total amount
of studied substance in the urine, and Div is the administered dose.
Renal clearance (ClR) of V-PYRRO/NO and V-PROLI/NO was calculated
as follows:






Hepatic elimination was determined using the ex vivo model of perfused
mouse liver. Following i.p. injection of ketamine (100 mg/kg), xylazine (10 mg/kg),
and 0.8 mg/kg of heparin, the vena porta and the vena cava inferior were cannulated
and ligated, and the liver was perfused using the U-100 system for organ perfusion
(Hugo Sachs Elektronik, Harvard Apparatus, March-Hugstetten, Germany) until
effluent was blood-free. The liver was than excised and moved to a moist chamber.
Perfusion was carried out with Krebs-Hanseleit buffer of the following composition:
118.0 mM NaCl, 2.52 mM CaCl2, 1.16 mM MgSO4, 24.88 mM NaHCO3, 1.18
mM KH2PO4, 4.7 mM KCl, 10.0 mM glucose, 2.0 mM pyruvic acid, and 0.5 mM
EDTA. After the initial stabilization period (15 minutes), either V-PYRRO/NO or
V-PROLI/NO was added at a final concentration of 10 or 50 mM, respectively. The
experiments were completed within 1 hour after starting perfusion. The perfusion
flow rate was 4.3 ml/min, and samples were collected as follows: inlet samples
every 20 minutes, and outlet effluents every 1 minute, between 5 and 20 minutes,
and then every 10 minutes. After the experiments, the livers were excised, dried,
and weighed.
To ensure the viability of the liver, alanine aminotransferase and lactate
dehydrogenase activity in the effluents were measured every 15 minutes for the
duration of the experiment by the enzymatic photometric method, using the
automatic biochemical analyzer Pentra 400 (Horiba, Kyoto, Japan), according
to the manufacturer’s instructions.
A control experiment to exclude the binding of V-PYRRO/NO or V-PROLI/NO
to the experimental setup was conducted. For this purpose, buffer containing
V-PYRRO/NO or V-PROLI/NO was perfused through the perfusion system
without mounting of the isolated liver. Buffer samples were collected the
same way as in the experiments with the isolated liver.
The hepatic extraction ratio was calculated based on the V-PYRRO/NO and
V-PROLI/NO concentrations in the inlet and outlet effluents:
E ¼ Cin 2Cout
Cin
ð4Þ
where E is the hepatic extraction ratio and Cin and Cout are concentrations of
studied compounds in inlet or outlet liver effluent.
Protein Binding
Binding of V-PYRRO/NO and V-PROLI/NO to bovine serum albumin (BSA)
and a-acid glycoprotein (AGP) was determined using capillary electrophoresis
in frontal analysis mode on a Beckman Coulter P/ACE MDQ CE system with
a photodiode array detector fixed at 230 nm (Beckman Coulter, Brea, CA). The
working conditions were as follows: uncoated fused silica capillary length
60.2 cm (50 cm to the detector) with 50-mm i.d. and 360-mm o.d.; temperature of
the capillary 37C; applied voltage of 15 kV; observed currents of about 56 mA.
Following the standard rinsing procedure, the samples were injected at 0.5 psi
for 40 seconds (injected sample volume represented 5% of the total capillary
volume). The unbound concentrations of V-PYRRO/NO and V-PROLI/NO were
determined by comparing the plateau peak height of the equilibrated samples with
the peak height of V-PYRRO/NO or V-PROLI/NO in the absence of BSA or AGP.
The results were expressed as the saturation fraction (r), representing the
number of moles of compound bound (Cb) per mole of protein (P):
r    ¼     Cb
P
ð5Þ
The percentage of binding was determined using eq. 6:
 %    bound      ¼       Ct 2   Cu
Ct
​ x  100 ​ ð6Þ
where Ct is the total concentration of compound in the protein solution, and Cu
is the free analyte concentration.
The equilibrium association constant (Ka) in the binding class (m) and the
number of binding sites (n) were determined by a nonlinear regression analysis





Kdi þ Cu     ð7Þ
where r is the number of moles of drug bound per mole of protein (Cb/Pt,
where Pt is the total protein concentration), m is the number of independent
classes of binding sites, Kdi is the dissociation constant for the ith class, and
ni is the number of binding sites in the ith class.
In Vitro Metabolism by Cytochrome P450
Rats were sacrificed by decapitation, and liver microsomes were prepared by
differential centrifugation. In brief, liver fragments were washed with 20 mM
Tris/KCl buffer (pH 7.4) and homogenized (IKA-Werke GmbH & Co. KG
Staufen, Janke, Germany). The homogenate was centrifuged (Sorvall WX Ultra
Series; Thermo Scientific, Waltham, MA) at approximately 11,500  g for 20
minutes at 4C. The supernatant (S9 fraction) was transferred to new tubes and
centrifuged at 100,000  g for 1 hour at 4C. The pellet was suspended in
0.15 M KCl and centrifuged again at 100,000  g for 1 hour at 4C. The
obtained pellet was dispersed in Tris/sucrose buffer and stored at 280C until
use. Protein concentration in the microsomal fraction was determined by Lowry
protein assay (Lowry et al., 1951).
V-PYRRO/NO or V-PROLI/NO at a concentration range of 0.5–50 mM was
incubated with the rat liver microsomes (1 mg/ml) in 0.1 M phosphate buffer
(pH 7.4) containing 10 mM MgCl2. After 5 minutes of preincubation at 37C,
the incubation reactions were initiated with the addition of NADPH to a final
concentration of 1 mM and were stopped after 20 minutes by placing samples on ice
and adding ice-cold acetonitrile containing internal standard (4-hydroxymephenytoin
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at a concentration of 20 ng/ml). Basic kinetic parameters, Vmax and Km for
V-PYRRO/NO and V-PROLI/NO, were calculated with GraphPad Prism
6.02 software (La Jolla, CA) using nonlinear regression.
To test the involvement of cytochrome P450 isoenzymes in V-PYRRO/NO
and V-PROLI/NOmetabolism, the following cytochrome P450–dependent isoenzyme
inhibitors were used: furafylline (1.5 mg/ml) for CYP1A2, sulfaphenazole (15 mg/ml)
for CYP2C9, (+)-N-3-benzylnirvanol (1 mg/ml) for CYP2C19, quinidine (15 mg/ml)
for CYP2D6, disulfiram (15 mg/ml) for CYP2E1, and ketoconazole (5 mg/ml) for
CYP3A4.
To study the effects of V-PYRRO/NO and V-PROLI/NO on cytochrome
P450 isoenzyme activity, a “cocktail” method was used based on measurement
of the concentration of metabolites derived from cytochrome P450 isoenzyme–
specific substrates. In brief, V-PYRRO/NO or V-PROLI/NO, in the con-
centration range of 0.1 mM to 1 mM, was incubated with rat liver microsomes
suspended in 0.1 M phosphate buffer (pH 7.4), 10 mM MgCl2, and substrate
cocktail, phenacetin (7.5 mg/ml) for CYP1A2, tolbutamide (2.5 mg/ml) for
CYP2C9, bufuralol (12.5 mg/ml) for CYP2D6, chlorzoxazone (12.5 mg/ml) for
CYP2E1, and midazolam (7 mg/ml) for CYP3A4. After addition of V-PYRRO/
NO or V-PROLI/NO, the reaction mixtures were preincubated for 5 minutes at
+37C in a shaking water bath (Grant Instruments, Royston, UK), and next the
reaction was initiated by addition of 1 mM NADPH. Following a 10-minute
incubation, the reaction was terminated with an ice-cold mixture of acetonitrile:
acetone (1:1; v/v) containing the internal standard dextrorphan (50 ng/ml). Samples
were subsequently cooled on ice for 20 minutes to precipitate the protein, and then
centrifuged at approximately 15,000  g for 15 minutes at 4C. The supernatant
was analyzed immediately after incubation.
Chromatographic and Mass Spectrometric Analysis
V-PYRRO/NO and V-PROLI/NO concentrations in plasma, liver homo-
genates, urine, liver effluents, and in the incubation mixture of micro-
somes (50 ml) were measured after deproteinization using ice-cold
acetonitrile (500 ml) containing internal standard (4-hydroxymephenytoin,
20 ng/ml). Samples were subsequently cooled on ice for 20 minutes to
precipitate the protein and then centrifuged at approximately 15,000  g for
15 minutes at 4C. The supernatant was transferred to a high-performance
liquid chromatography vial, and 5 ml of supernatant was injected into the
analytical column. The analytical system consisted of UFLC Nexera
(Shimadzu, Kyoto, Japan) coupled with a QTrap 5500 mass spectrometer
(AB Sciex, Framingham, MA). Chromatographic separation was achieved
using the Acquity UPLC BEH C18 (1.7 mm, 3.0  100 mm; Waters, Milford,
MA) analytical column, with acetonitrile and water containing 0.1% formic
acid in the isocratic elution (45:55 v/v), at a flow rate of 0.4 ml/min. The
analyzed compounds were detected in positive ionization multiple reaction
monitoring mode, monitoring the transitions of protonated ions m/z 158→70
for V-PYRRO/NO, m/z 202→100 for V-PROLI/NO, and m/z 235→150 for
internal standard. The operating conditions were as follows: curtain gas
20 psi, ion spray voltage 5000 V, temperature 400C, ion source gases 50 and
15 psi. Nitrogen was used as the curtain and collision gas.
Chromatographic separation of the metabolites of model cytochrome P450
substrates was performed on a Kinetex analytical column (2.6 mm PFP 100 Å,
3 100 mm; Phenomenex, Torrance, CA) using an Ultimate 3000 Ultra Performance
Liquid Chromatography system (Dionex, Sunnyvale, CA). The mobile phase
consisted of acetonitrile containing 0.1% formic acid (eluent A) and water
containing 0.1% formic acid (eluent B). At a flow rate of 500 ml/min, the amount
of eluent A was increased linearly from 20 to 95% over 2 minutes, maintained at
95% for 6 minutes, returned to 20% over 3 minutes, and left to re-equilibrate for 6
minutes. The total run time was 15 minutes. The analytes were detected using
a TSQ Quantum Ultra triple quadrupole mass spectrometer (Thermo Scientific).
Heated electrospray ionization was used in both positive and negative mode (for
6-hydroxychlorzoxazone). The selected reaction monitoring transitions for each
quantified substance and the internal standard were as follows: acetaminophen m/z
152→110, 4-hydroxytolbutamide m/z 287→89, 4-hydroxymephenytoin m/z 235→150,
1-hydroxybufuralol m/z 278→186, 6-hydroxychlorzoxazone m/z 184→120,
1-hydroxymidazolam m/z 342→324, 4-hydroxymidazolam m/z 342→297,
and dextrorphan (internal standard) m/z 258→157. The operating conditions
were as follows: needle voltage 4020 V, vaporizer temperature 250C, sheath
gas (nitrogen) pressure 30 psi, auxiliary gas (nitrogen) pressure 10 psi, and
capillary temperature 370C. The argon gas pressure in the collision cell was
approximately 2 mTorr.
Nitrite and Nitrate Measurements
The plasma samples were precipitated with methanol at a ratio of 1:1 (v/v).
Liver samples were homogenized with methanol at a ratio of 1:2 (w/v).
Following centrifugation at 10,000  g for 10 minutes, 10 ml of supernatant
was injected into the separation column.
The concentrations of nitrite and nitrate were measured by ENO-20 system
(Eicom, Kyoto, Japan), based on the liquid chromatography method with
postcolumn derivatization with Griess reagent. Nitrite and nitrate were separated
on a NO-PAK column (4.6  50 mm; Eicom). Nitrate was reduced to nitrite by
a cadmium-copper column (NO-RED; Eicom). Nitrite was detected based on the
Griess reaction, with sulfanilamide and naphthylethylenediamine forming a purple
diazo compound with the absorbance of dye product measured at 540 nm. The
flow of the mobile phase (carrier solution; Eicom) was 0.33 ml/min. The Griess
reagent was delivered at a flow rate of 0.11 ml/min.
Statistical Analysis
Data are expressed as the mean 6 S.E.M. The assessment of normality
and heterogeneity of variances was performed using the Shapiro-Wilk test
and Fligner-Killeen test, respectively. To assess the statistical significance of
the pharmacokinetics results, Student’s t test and the nonparametric Mann-
Whitney test were used. For pharmacological experiments, the nonparametric
Kruskal-Wallis test or one-way analysis of variance and Tukey’s post-hoc
test were used. The results were analyzed using Statistica 10.0 software
(Statsoft, Tulsa, OK).
Results
Effects of V-PYRRO/NO and V-PROLI/NO Treatment on
NAFLD. Treatment with V-PYRRO/NO, but not V-PROLI/NO, attenuated
liver steatosis as evidenced by histopathological analysis (Fig. 2, A–C)
with semiautomatic quantitative analysis of liver fat content based on
Oil Red O–stained slides (Fig. 2D), as well as by liver triglyceride content
based on gas chromatography–flame ionization detector chromatography
(Fig. 2E). Furthermore, V-PYRRO/NO, but not V-PROLI/NO, favorably
changed fatty acid composition by increasing the PUFA/SFA ratio in
mice fed a HFD (Fig. 2F). Finally, the overall glucose exposure,
calculated on the basis of AUC of blood glucose concentration versus
time on the tolerance chart, was significantly improved in V-PYRRO/
NO–treated mice, whereas there was no improvement seen in V-PROLI/
NO–treated mice (Fig. 2, G and H).
Pharmacokinetic Profile of V-PYRRO/NO and V-PROLI/NO.
The mean plasma concentration versus time profiles of V-PYRRO/NO
and V-PROLI/NO after i.v. and i.p. administration are depicted in Fig.
3A, and the pharmacokinetic parameters are given in Table 1.
V-PYRRO/NO was eliminated more rapidly than V-PROLI/NO, as
evidenced by a lower mean residence time and higher clearance values.
V-PYRRO/NO was detectable in plasma for up to 60 minutes after i.v.
administration and 30 minutes after i.p. administration, respectively,
whereas V-PROLI/NO was measurable over the entire sampling period.
Moreover, V-PYRRO/NO was widely distributed in the intra- and
extracellular water (Vdss [steady -state volume of distribution] = 0.88
l/kg), whereas V-PROLI/NO distribution was limited to the extracellular
fluid (Vdss = 0.15 l/kg). In view of the fact that the pharmacological
effects were studied following intraperitoneal administration of
V-PYRRO/NO and V-PROLI/NO, pharmacokinetic studies follow-
ing i.p. dosing were also conducted. Both compounds were rapidly
absorbed after i.p. administration, with lower bioavailability for
V-PYRRO/NO as compared with V-PROLI/NO (about 28 and 51%,
respectively). Systemic NO release following i.v. administration of
V-PYRRO/NO was higher than with V-PROLI/NO, as evidenced by
nitrate and nitrite plasma concentrations (Fig. 3, B and C).
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Hepatic Metabolism of V-PYRRO/NO and V-PROLI/NO. To
assess the liver disposition of V-PYRRO/NO and V-PROLI/NO, the
concentration of each compound in liver homogenates was measured
following i.v. or i.p. administration of the compounds. V-PYRRO/NO
was not detectable, whereas V-PROLI/NO was distributed in the liver
with maximum concentrations of 35.8 nmol/g (tmax [time to reach the
Fig. 2. Representative pictures of liver sections stained with H&E (A), one-step Gomori’s trichrome (B), and Oil Red O (C). Liver fat content calculated from Oil Red O
pictures (D), liver triglyceride (TG) concentration (E), and PUFA/SFA ratio (F) in the liver of mice. Glucose tolerance curve (G) and AUC of blood glucose concentration
versus time (H). Values are the means6 S.E.M. (n = 6). Values with different superscript letters within each animal group are significantly different (P# 0.05). HF, high-fat
group; HF+V-PYRRO/NO, high-fat group treated with V-PYRRO/NO; HF+V-PROLI/NO, high-fat group treated with V-PROLI/NO.
Fig. 3. Comparison of plasma pharmacokinetic profiles of V-PYRRO/NO and V-PROLI/NO after i.v. and i.p. administration in mice (A), and NO2
2, NO3
2 concentrations
in plasma after i.v. administration of each compound (B and C). Values are expressed as the mean 6 S.E.M. (n = 3 for i.p. and n = 4 for i.v. administration).
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maximal concentration] = 2 minutes) and 23.9 nmol/g (tmax = 7 minutes)
following i.v. and i.p. administration, respectively. Even after 60 minutes,
the concentration of V-PROLI/NO remained elevated (5.3 and 2.5 nmol/g
after i.v. and i.p., respectively).
To compare the decomposition of V-PYRRO/NO and V-PROLI/NO
in the liver in greater detail, the uptake and metabolism of these analogs
were studied in the isolated, perfused mouse liver setup. V-PYRRO/NO
exhibited nonspecific binding to the experimental setup, resulting in
a 25% decrease in the dose introduced to the liver that was included
in the calculations of the hepatic extraction ratio, whereas binding of
V-PROLI/NO to the perfusion setup was not significant. As shown in
Fig. 4, A and B, the concentrations of V-PYRRO/NO in the liver
effluents amounted to about 70% of the initial concentration, taking into
account the binding to experimental setup; therefore, the calculated
hepatic extraction ratio was about 0.3, and the hepatic clearance was
0.058 l/min/kg. In contrast, V-PROLI/NO was hardly metabolized in the
liver, with outflow concentrations of the compound near its inflow
concentration. The hepatic extraction ratio for V-PROLI/NO was below
0.1 (about 0.05) and hepatic clearance was 0.0005 ml/min/kg, suggesting
negligible liver metabolism of V-PROLI/NO, in contrast with V-PYRRO/
NO. These findings were confirmed by the measurements of concen-
trations of nitrite and nitrate in the liver samples after a 1-hour perfusion
of V-PYRRO/NO or V-PROLI/NO at a concentration of 50 mM.
V-PYRRO/NO perfusion resulted in elevations in nitrite and nitrate liver
content by more than 2-fold (NO2
2: 4.8 nmol/g; NO3
2: 23.3 nmol/g),
whereas V-PROLI/NO perfusion did not increase nitrite or nitrate
concentration in the liver homogenate (NO2
2: 1.7 nmol/g; NO3
2: 13.4
nmol/g). Altogether, these results confirm considerable liver metabolism
of V-PYRRO/NO, with subsequent NO release, but not of V-PROLI/NO.
Renal Elimination of V-PYRRO/NO and V-PROLI/NO. As
shown in Fig. 4C, less than 0.1% of V-PYRRO/NO was eliminated in
the urine, whereas approximately 61% of V-PROLI/NO was excreted
in the urine as unmodified compound. The calculated renal clearance
for V-PYRRO/NO was very low and without physiologic significance,
whereas the renal clearance for V-PROLI/NO was significantly higher
and amounted to 0.0032 l/min/kg.
Protein Binding of V-PYRRO/NO and V-PROLI/NO. Both
analogs bound to BSA with one class of binding site, and the per-
centage of binding amounted to 25.13 6 4.5% and 53.33 6 7.1% for
V-PYRRO/NO and V-PROLI/NO, respectively. However, binding affinity
to BSA was relatively low (Ka = 1.93  103 and 7.57  103 M21 for
V-PYRRO/NO and V-PROLI/NO, respectively). Binding of studied
analogs to AGP was also very low and not of physiologic significance
(3.15 6 2.9 and 3.05 6 1.43 for V-PYRRO/NO and V-PROLI/NO,
respectively), probably due to the acidic character of these molecules.
Role of Cytochrome P450 in V-PYRRO/NO and V-PROLI/NO
Metabolism. The calculated kinetic parameters derived using the
Michaelis-Menten transformation (Fig. 5A) for V-PYRRO/NO were
Km = 131.6 6 38.15 mM and Vmax = 6.35 6 1.41 mmol/min/mg
protein. Based on the kinetic plots, V-PROLI/NO seems to have a low
affinity for the cytochrome P450 isoenzymes. The Eadie-Hofstee plots
were nonlinear, suggesting multiple-enzyme catalysis (data not shown).
The effect of selective cytochrome P450 inhibitors on the bio-
transformation of V-PYRRO/NO and V-PROLI/NO using isoenzyme-
selective chemical inhibitors is shown in Fig. 5B. As evidenced by the
effects of their respective inhibitors, V-PYRRO/NO was metabolized
mainly by CYP2E1, but also by CYP2C9, CYP1A2, and CYP3A4,
whereas V-PROLI/NO was biotransformed mainly by CYP1A2 and
CYP2C9.
Neither V-PYRRO/NO nor V-PROLI/NO inhibited cytochrome
P450 isoenzymes as evidenced by the lack of inhibition of phenacetin-
O-deethylation (CYP1A2), tolbutamide-4-hydroxylation (CYP2C9),
bufuralol-1-hydroxylation (CYP2D6), chlorzoxazone-6-hydroxylation
(CYP2E1), and midazolam-1- and -4-hydroxylation (CYP3A4), up to
a concentration of 1 mM V-PYRRO/NO and V-PROLI/NO (data not
shown).
Discussion
In the present study, we compared two NO donors (V-PYRRO/NO
and V-PROLI/NO) that were designed to deliver NO to the liver via
cytochrome P450–dependent metabolism by looking at their effects on
liver steatosis, liver fatty acid composition, and insulin resistance, and
comprehensively analyzing their pharmacokinetics and metabolism
profiles. In the study, we demonstrated that, despite having similar
chemical structures, only V-PYRRO/NO attenuated liver steatosis,
increased the liver PUFA/SFA ratio, and improved postprandial
glucose tolerance, whereas V-PROLI/NO was ineffective. Pharmaco-
kinetic studies revealed rapid absorption following i.p. administration,
TABLE 1
Pharmacokinetic parameters of V-PYRRO/NO and V-PROLI/NO after i.v. and i.p.
administration in control mice
Parameter
V-PYRRO/NO V-PROLI/NO
Intravenous Intraperitoneal Intravenous Intraperitoneal
Co (mM) 41.5 — 222.48 —
AUC0→‘ (mM*min) 218.62 60.9 5669.26 2895.27
MRT (min) 6 7.7 27.87 28.57
Cmax (mM) — 7.93 — 79.57
tmax (min) — 5 — 10
Vss (l/kg) 0.88 — 0.149 —
Cl (l/min/kg) 0.146 — 0.0053 —
F (%) — 27.85 — 51.07
AUC0→‘, area under the curve extrapolated to infinity; Cl, clearance; Co, initial concentration;
MRT, mean residence time; tmax, the time to reach the maximum plasma concentration;
Vss, steady-state volume of distribution.
Fig. 4. Calculated differences for V-PYRRO/NO and V-PROLI/NO concentrations between inlet and outlet effluent samples following perfusion with 10 mM (A) and
50 mM compound (B). (C) Fraction of dose that was eliminated unchanged by the kidney. Values are expressed as the mean 6 S.E.M. *P , 0.05; **P , 0.01 (n = 4 for
isolated, perfused mouse liver experiments, and n = 7 for renal elimination evaluation).
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intense elimination, and incomplete bioavailability for both V-PYRRO/NO
and V-PROLI/NO. However, it was noticed that V-PYRRO/NO was
metabolized in the liver by CYP2E1, CYP2C9, and CYP3A4, whereas
V-PROLI/NO was eliminated mostly in unchanged form by the kidney.
Importantly, V-PYRRO/NO proved to be a better NO releaser in the
mouse in vivo and in the isolated liver as compared with V-PROLI/NO.
These results were consistent with superior antisteatotic activity for
V-PYRRO/NO. In conclusion, we provide clear-cut evidence that
V-PYRRO/NO displays a pronounced antisteatotic effect associated
with liver-targeted NO release, whereas V-PROLI/NO is not effective,
is not taken up by the liver, and is eliminated mostly unchanged by the
kidney.
In physiological conditions, NO generated mainly by endothelial
nitric oxide synthase (Förstermann and Sessa, 2012) plays a crucial
role in liver homeostasis. NO activates soluble guanyl cyclase, which
activates cGMP-dependent protein kinase (Pfeifer et al., 2013), and its
role is not limited to the regulation of hepatic arterial resistance
(Rockey and Shah, 2004). In fact, the NO/cGMP–dependent signaling
pathway exerts an anti-inflammatory and antifibrotic effect by limiting
Kupffer cell and hepatic stellate cell activation (Tateya et al., 2011).
NO also inhibits caspase activation, and therefore apoptosis, in hepatocytes
(Kim et al., 2000a). Furthermore, the remarkable regenerative ability of the
liver is linked to NO activity (Carnovale and Ronco, 2012). NO also
regulates glucose and lipid metabolism (Jobgen et al., 2006), decreases fatty
acid storage by improving their catabolism, and attenuates de novo fatty
acid synthesis. Moreover, NO regulates glucose metabolism by increasing
glucose transport and metabolism as well as inhibiting gluconeogenesis and
glycogen deposition (Jobgen et al., 2006).
Clearly, inadequate NO production by liver sinusoidal endothelial
cells results in unopposed hepatic stellate cell activation and promotion of
liver inflammation, which may contribute to the progression of portal
hypertension (Hu et al., 2013), sinusoidal obstruction syndrome (DeLeve,
2008), ischemia-reperfusion injury (Siriussawakul et al., 2010), and liver
steatosis (Maslak et al., 2015). In fact, impairment of NO signaling
resulted in decreased glucose uptake, fasting hyperglycemia, and the
development of insulin resistance (Lutz et al., 2011; An et al., 2012).
In line with the importance of NO in the maintenance of metabolic
homeostasis, the beneficial effect of NO-based therapy has been
demonstrated in obesity (Jobgen et al., 2009), insulin resistance (Sadri
and Lautt, 1999), and liver steatosis (de Oliveira et al., 2006).
However, in contrast to the present paper, none of these reports
concerned the direct delivery of NO to the liver (Ricardo et al., 2002).
In the current study, we aimed at comparing the antisteatotic efficacy of
two structurally related hepatocyte-specific NO donors, and revealed
a hepatospecific and hepatoprotective action of V-PYRRO/NO, but not
of V-PROLI/NO, against NAFLD. Moreover, the liver-specific effects
of V-PYRRO/NO–derived NO release not only attenuated liver steatosis,
but were also associated with changes in fatty acid composition, in
particular the amelioration of the PUFA/SFA ratio, most likely due to
inhibition of endogenous fatty acid synthesis. Our findings are of particular
importance because fatty acid saturation has been shown to be involved in
the pathogenesis of insulin resistance (van den Berg et al., 2010) and
metabolic syndrome (Warensjö et al., 2005). In fact, in our previous work,
we demonstrated that the effect of V-PYRRO/NO on insulin resistance and
steatosis was mediated by NO-dependent Akt activation and inhibition
of de novo fatty acid synthesis by Acetyl-CoA carboxylase (ACC)
phosphorylation (Maslak et al., 2015). Interestingly, despite previously
reported data indicating NO release in vitro (Hong et al., 2010) and
favorable toxicity (Chakrapani et al., 2007), V-PROLI/NO did not
influence insulin resistance and fatty acid composition in mice in the
present study.
The superior pharmacological activity of V-PYRRO/NO was not
associated with higher bioavailability than V-PROLI/NO following
i.p. administration. In fact, V-PROLI/NO showed greater bioavail-
ability (51%) than V-PYRRO/NO (27%). Similar results for the bio-
availability of V-PYRRO/NO were reported by Stinson et al. (2002).
The incomplete bioavailability, besides the first-pass effect, might be
a result of extrahepatic metabolism of V-PYRRO/NO and V-PROLI/
NO, since the cytochrome P450 enzyme system is also located in other
extrahepatic tissues, including the lungs, kidneys, and small intestine
(Guengerich, 1992; Nebert and Russell, 2002; Ding and Kaminsky,
2003; Paine et al., 2006; Pavek and Dvorak, 2008). Partial de-
composition of V-PYRRO/NO and V-PROLI/NO in other organs may
explain the increased nitrite and nitrate plasma concentrations detected
following i.v. administration of the compounds. However, we are
confident that, even though V-PYRRO/NO was partially metabolized
in extrahepatic tissues, its pharmacological effect came mostly, if not
entirely, from liver-specific NO release.
The results from the specific cytochrome P450 inhibitors demon-
strated that V-PYRRO/NO was mainly a substrate for CYP2E1, as
well as for CYP1A2, CYP2C9, and CYP3A4, whereas V-PROLI/NO
was shown to be metabolized mainly by CYP1A2 and CYP2C9 in the
liver. These results are partially in line with the findings of Inami et al.
(2006), who showed that CYP2E1, CYP2A6, and CYP2B6 are
responsible for V-PYRRO/NO metabolism in human liver micro-
somes. On the other hand, V-PROLI/NO was metabolized mainly
by CYP1A2 and, to a lesser extent, by CYP2E1 and CYP3A4, as
reported previously (Chakrapani et al., 2007), but with low enzyme
affinity.
Increased metabolism and NO production in V-PROLI/NO–treated
HepG2 cells, as compared with V-PYRRO/NO treatment, was previously
demonstrated by Hong et al. (2010). However, high concentrations of
Fig. 5. (A) Michaelis-Menten plots of the enzyme kinetics of V-PYRRO/NO and V-PROLI/NO in rat liver microsomes. (B) The effect of selective cytochrome P450
inhibitors on V-PYRRO/NO and V-PROLI/NO (50 mM) metabolism in rat liver microsomes. Values are shown as the mean percentage 6 S.E.M. (n = 3 for furafylline,
sulfaphenazole, N-benzylnirvanol, and ketoconazole; n = 6 for disulfiram).
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V-PYRRO/NO and V-PROLI/NO were required to generate relatively
low concentrations of nitrite [reported by Hong et al., 2010 and
confirmed by us (unpublished results)], suggesting a relatively low
biotransformation of the compounds in HepG2 cells. This notion seems
to be in line with recent studies showing that, in human hepatoma cells
(e.g., HepG2), the expression of most of cytochrome P450 isoenzymes
is substantially reduced as compared with primary human hepatocytes
(about 100- to 1000-fold lower) (Westerink and Schoonen, 2007;
Pawłowska and Augustin, 2011; Lin et al., 2012). Moreover, in HepG2
cell lines, the activity of cytochrome P450 enzymes is much lower than
in ex vivo isolated primary hepatocytes (Westerink and Schoonen,
2007; Lin et al., 2012). Additionally, since the expression and activity of
CYP1A2 are higher than those of CYP2E1 in HepG2 cells (Westerink
and Schoonen, 2007), Hong et al. (2010) found high release of NO from
V-PROLI/NO, as compared with V-PYRRO/NO. In our hands, bio-
transformation of V-PROLI/NO was dependent on CYP1A2 and
CYP2C9, whereas biotransformation of V-PYRRO/NO was mainly
dependent on CYP2E1. It is not surprising that Gong et al. (2004)
demonstrated that HepG2 cells failed to generate nitrite and nitrate
from V-PYRRO/NO. Accordingly, we believe that use of the HepG2
cell line as a model system to study NO release from V-PYRRO/NO
and V-PROLI/NO is not relevant to primary hepatocytes or the in
vivo setting, thus giving contradictory results from our present
study, which was performed in an in vivo and ex vivo isolated liver
setup.
In the present work, we also demonstrated that the differences in the
plasma pharmacokinetic profiles of V-PYRRO/NO and V-PROLI/NO
may be linked to differences in their lipophilicity caused by an ad-
ditional carboxylic acid moiety in V-PROLI/NO’s structure. In silico–
predicted log P values for both analogs differed from 21.63 to
1.01 for V-PYRRO/NO and from 23.92 to 22.76 for V-PROLI/NO,
depending on the pH of the environment. V-PYRRO/NO, being more
lipophilic, was widely distributed in the total body water (Vdss = 0.88
l/kg), whereas V-PROLI/NO distribution was limited only to the
extracellular fluid (Vdss = 0.149 l/kg). Differences in pharmacokinetic
profiles can also be related to the participation of proline transporters
in the case of V-PROLI/NO, but not of V-PYRRO/NO.
Moreover, the results showed that the affinity of V-PYRRO/NO and
V-PROLI/NO to BSA was rather low. V-PROLI/NO was bound to
BSA to a greater extent, probably due to the stronger acidic character,
which can partially explain its slower elimination and longer biological
half-life. Furthermore, we provide evidence that neither compound
affects the activity of cytochrome P450, as shown in the direct inhibition
study. In summary, both analogs display distinct cytochrome P450
metabolism, distinct pharmacokinetic profile, and differences in renal
excretion.
Conclusions
V-PYRRO/NO, but not V-PROLI/NO, protected against high fat
diet-induced liver steatosis and improved insulin resistance in mice
fed a high-fat diet. The compounds’ distinct pharmacological effects
can be explained by their pharmacokinetic and metabolic profiles.
V-PYRRO/NO displayed a pronounced antisteatotic effect associated
with liver-targeted NO release, whereas V-PROLI/NO was ineffective,
not taken up by the liver, and was eliminated mostly unchanged by the
kidney. It is worth adding that therapy with liver-targeted NO donors,
free of systemic hypotensive effects, represents a promising therapeutic
strategy not only in NAFLD but also in other liver disorders, such as
liver cirrhosis, liver fibrosis, and postischemic injury (Ricciardi et al.,
2001; Moal et al., 2002; Edwards et al., 2008) that warrants further
studies.
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